NCT03740516

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 31, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 14, 2018

Completed
Last Updated

April 29, 2020

Status Verified

April 1, 2020

First QC Date

October 31, 2018

Last Update Submit

April 27, 2020

Conditions

Bechet's Disease

Keywords

Expanded AccessCompassionate Use

Interventions

CC-10004DRUG

CC-10004 will be administered orally

Also known as: Apremilast, Otezla

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Celgene

Summit, New Jersey, 07901, United States

Location

MeSH Terms

Interventions

apremilast

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2018

First Posted

November 14, 2018

Last Updated

April 29, 2020

Record last verified: 2020-04

Locations

US(1)